Takeda Pharmaceutica

4502
End-of-day quote Tokyo - 02/19
4500JPY
-0.18%
Income Statement Evolution
Annual Income Statement Data
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Sales1 770 5312 463 170
EBITDA437 460538 767
Operating profit (EBIT)--
Pre-Tax Profit (EBT)217 205221 296
Net income186 886179 678
EPS ( JPY )239134
Dividend per Share ( JPY )180180
Yield3,47%3,99%
Announcement Date05/14/2018
06:00am
-
Finances - Leverage
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Debt610 4945 789 399
Finance--
Operating income (EBITDA)437 460538 767
Leverage
(Debt/EBITDA)
1,40x10,7x
Capital Expenditure67 005142 914
Book Value Per Share (BVPS)2 557  JPY3 736  JPY
Cash Flow per Share490  JPY314  JPY
Announcement Date05/14/2018
06:00am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 7 055 042 M JPY -
Entreprise Value (EV) 12 844 441 M JPY 12 390 817 M JPY
Valuation 2019e 2020e
P/E ratio (Price / EPS) 33,6x
Capitalization / Revenue 2,86x 2,01x
EV / Revenue 5,21x 3,53x
EV / EBITDA 23,8x 12,6x
Yield (DPS / Price) 3,99% 3,99%
Price to book (Price / BVPS) 1,21x 1,42x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) - -
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) 7,29% 1,60%
ROA (Net Profit / Asset) 1,96% 2,90%
ROE (Net Profit / Equities) 4,02% 4,28%
Rate of Dividend 134% -54 579%
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   5,80% 5,94%
Cash Flow / Sales 19,8% 25,8%
Capital Intensity (Assets / Sales) 3,72x 0,55x
Financial Leverage (Net Debt / EBITDA) 10,7x 5,44x
Price Earning Ratio
BNA & Dividende